Axogen, Inc. (AXGN)

Over the past six months, Axogen's stock has experienced upward momentum. In October 2025, Axogen reported strong third-quarter performance with revenue growing 23.5% to $60.1 million and adjusted EBITDA of $9.2 million. The FDA extended the PDUFA goal date for the Avance Nerve Graft BLA approval to December 5, 2025. In January 2026, Axogen filed an omnibus shelf registration and pursued follow-on equity offerings, and the stock saw an analyst upgrade.

Axogen experiences typical seasonality in its demand, particularly in the fourth quarter. The company's products are utilized in both scheduled and emergent procedures.

Axogen, Inc. is a medical technology company specializing in surgical solutions for peripheral nerve regeneration and repair. Its core business focuses on restoring nerve function and improving the quality of life for patients with peripheral nerve injuries. The company's major products include Avance Nerve Graft, a processed human nerve allograft; AxoGuard Nerve Connector, a coaptation aid for tensionless nerve repair; AxoGuard Nerve Protector, a product that wraps and protects damaged nerves; AxoGuard HA+ Nerve Protector, a next-generation product with a hyaluronate-alginate gel coating; Avive+ Soft Tissue Matrix, an amniotic membrane allograft; and AxoGuard Nerve Cap, a product used to protect a nerve end and reduce neuroma development.

Axogen's products are available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries. The company's operations originated near the University of Florida in Gainesville, Florida, and its current headquarters are in Alachua, Florida.

Axogen's brand reputation appears to be strong and positive, driven by robust revenue growth, clinical validation from medical societies, the anticipated FDA BLA approval for Avance Nerve Graft, and increased payer coverage for nerve repair.

Institutional investors hold a significant majority of Axogen's stock, accounting for approximately 84.74% to 88% of shares outstanding. Major institutional owners include First Light Asset Management, LLC, BlackRock, Inc., Vanguard Group Inc., Morgan Stanley, ArrowMark Colorado Holdings LLC, Soleus Capital Management, L.P., Wasatch Advisors Inc., Assenagon Asset Management S.A., and Balyasny Asset Management Llc. Individual investors, including insiders, hold a smaller percentage, with insider ownership typically under 5%.